Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Respiratory Drugs >  Asthma drugs >  Suplatast tosilate

Suplatast tosilate

Basic information Safety Supplier Related

Suplatast tosilate Basic information

Product Name:
Suplatast tosilate
Synonyms:
  • (2-(4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl)ethyl)dimethylsulfonium p-toluenesulfonate
  • 2-[4-(2-Hydroxy-3-ethoxypropoxy)phenylcarbamoyl]ethyldimethylsulfonium·4-methylbenzenesulfonate
  • IPD-1151T
  • S,S-Dimethyl-3-oxo-3-[4-(2-hydroxy-3-ethoxypropoxy)anilino]propane-1-sulfonium·4-methylbenzenesulfonate
  • [2-[[[4-(2-Hydroxy-3-ethoxypropoxy)phenyl]amino]carbonyl]ethyl]dimethylsulfonium
  • [2-[4-(2-Hydroxy-3-ethoxypropoxy)phenylcarbamoyl]ethyl]dimethylsulfonium
  • [3-Oxo-3-[4-(2-hydroxy-3-ethoxypropoxy)phenylamino]propyl]dimethylsulfonium
  • 2-[4-(2-Hydroxy-3-ethoxypropoxy)phenylcarbamoyl]ethyldimethylsulfonium
CAS:
94055-76-2
MF:
C23H33NO7S2
MW:
499.64062
Product Categories:
  • API
  • Aromatics
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Sulfur & Selenium Compounds
  • IPD 1151T
Mol File:
94055-76-2.mol
More
Less

Suplatast tosilate Chemical Properties

Melting point:
84-87°C
storage temp. 
Inert atmosphere,Room Temperature
solubility 
DMSO: >20mg/mL
form 
powder
color 
white to off-white
Merck 
14,9003
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months.
InChIKey
RYVJQEZJUFRANT-UHFFFAOYSA-N
SMILES
C1(NC(=O)CC[S+](C)C)=CC=C(OCC(O)COCC)C=C1.C1(S([O-])(=O)=O)=CC=C(C)C=C1
CAS DataBase Reference
94055-76-2(CAS DataBase Reference)
More
Less

Safety Information

WGK Germany 
3
RTECS 
WR7906000
HS Code 
2930.90.2900
Toxicity
LD50 in male, female mice, male, female rats (mg/kg): 81, 96, 96, 93 i.v.; in mice, rats (g/kg): >12.5, >10 orally (Yamashita)
More
Less

Suplatast tosilate Usage And Synthesis

Description

Suplatast tosylate is a unique dimethylsulfonium salt marketed in Japan for the treatment of bronchial asthma, atopic dermatitis and allergic rhinitis. Suplatast tosylate is a potent inhibitor of IgE synthesis without suppressing IgM and IgG. The mechanism of action for suplatast tosylate is thought to be via the inhibition of interleukin-4 and interleukin-6 production by T-cells at the gene level. In allergic patients, suplatast tosylate markedly improved clinical symptoms which correlated with a significant decrease in serum IgE antibody levels.

Description

Suplatast is an antiallergic agent. It inhibits IL-4 and IL-5 production in conalbumin-stimulated D10.G4.1 murine T helper 2 (Th2) cells in a concentration-dependent manner. Suplatast (100 mg/kg) inhibits ovalbumin-induced increases in eosinophil and total cell numbers, as well as IL-4, IL-5, and IL-13, but not IFN-γ, levels in bronchoalveolar lavage fluid (BALF) in an ovalbumin-sensitized mouse model of asthma. It also inhibits ovalbumin-induced increases in ovalbumin-specific IgE in serum and bronchial hyperresponsiveness to methacholine in the ovalbumin-sensitized mouse model of asthma.

Originator

Taiho (Japan)

Uses

Suplatast Tosylate is an antiallergic drug. Suplatast Tosylate inhibits antigen-induced histamine release from mast cells as well as IgE antibody formation. Suplatast Tosylate suppresses interleukin (IL)-4 release from T cells, however in human peripheral basophils, Suplatast Tosylate inhibited the antigen-induced release of IL-13 but not IL-4.

Uses

Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.

brand name

IPD

Biological Activity

Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN- γ production. Acts as an immunoregulator that suppresses IgE production, eosinophil infiltration and histamine release. Exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.

References

[1] Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo
[2] LI-WEN HSU . The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells[J]. Transplant immunology, 2007, 18 2: Pages 108-114. DOI:10.1016/j.trim.2007.05.008
[3] MAKOTO FURONAKA. Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice.[J]. Journal of Pharmacology and Experimental Therapeutics, 2009, 328 1: 55-61. DOI:10.1124/jpet.108.141721
[4] DEBAPRIYA BHATTACHARYA. Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis.[J]. The Journal of Biological Chemistry, 2014, 289 48: 33404-33411. DOI:10.1074/jbc.m114.600452
[5] MARIKO WADA . Effect of Suplatast Tosilate on Antileukotriene Non-Responders with Mild-to-Moderate Persistent Asthma[J]. Allergology International, 2009, 58 3: Pages 389-393. DOI:10.2332/allergolint.08-oa-0068

Suplatast tosilateSupplier

Chongqing Zein Pharmaceutical Co., Ltd, Gold
Tel
023-68889003
Email
zhienyaoye@zhienyaoye.com
J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Email
jkinfo@jkchemical.com
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
4006356688 18621169109
Email
market03@meryer.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com